236 related articles for article (PubMed ID: 34818873)
1. The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial.
Kovacevic KD; Grafeneder J; Schörgenhofer C; Gelbenegger G; Gager G; Firbas C; Quehenberger P; Jilma-Stohlawetz P; Bileck A; Zhu S; Gilbert JC; Beliveau M; Jilma B; Derhaschnig U
Haematologica; 2022 Sep; 107(9):2121-2132. PubMed ID: 34818873
[TBL] [Abstract][Full Text] [Related]
2. The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin.
Kovacevic KD; Buchtele N; Schoergenhofer C; Derhaschnig U; Gelbenegger G; Brostjan C; Zhu S; Gilbert JC; Jilma B
Sci Rep; 2020 Jul; 10(1):11180. PubMed ID: 32636459
[TBL] [Abstract][Full Text] [Related]
3. The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer.
Zhu S; Gilbert JC; Hatala P; Harvey W; Liang Z; Gao S; Kang D; Jilma B
J Thromb Haemost; 2020 May; 18(5):1113-1123. PubMed ID: 32011054
[TBL] [Abstract][Full Text] [Related]
4. The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease.
Ay C; Pabinger I; Kovacevic KD; Gelbenegger G; Schörgenhofer C; Quehenberger P; Jilma-Stohlawetz P; Sunder-Plassman R; Gilbert JC; Zhu S; Jilma B; Derhaschnig U
Blood Adv; 2022 Sep; 6(18):5467-5476. PubMed ID: 35772170
[TBL] [Abstract][Full Text] [Related]
5. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
6. The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients.
Kovacevic KD; Greisenegger S; Langer A; Gelbenegger G; Buchtele N; Pabinger I; Petroczi K; Zhu S; Gilbert JC; Jilma B
Sci Rep; 2021 Feb; 11(1):3092. PubMed ID: 33542410
[TBL] [Abstract][Full Text] [Related]
7. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.
Casonato A; Pontara E; Sartorello F; Cattini MG; Sartori MT; Padrini R; Girolami A
Blood; 2002 Jan; 99(1):180-4. PubMed ID: 11756169
[TBL] [Abstract][Full Text] [Related]
8. Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium.
Stel HV; Sakariassen KS; Scholte BJ; Veerman EC; van der Kwast TH; de Groot PG; Sixma JJ; van Mourik JA
Blood; 1984 Jun; 63(6):1408-15. PubMed ID: 6426553
[TBL] [Abstract][Full Text] [Related]
9. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
[TBL] [Abstract][Full Text] [Related]
10. The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.
Johnstone IB; Crane S
Can J Vet Res; 1987 Apr; 51(2):189-93. PubMed ID: 3111674
[TBL] [Abstract][Full Text] [Related]
11. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
13. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.
Fricke WA; Brinkhous KM; Garris JB; Roberts HR
Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998
[TBL] [Abstract][Full Text] [Related]
14. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
15. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
18. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
[TBL] [Abstract][Full Text] [Related]
19. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
20. Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
Kao KJ; Pizzo SV; McKee PA
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5317-20. PubMed ID: 315561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
